Effects of Resveratrol Supplementation on Oocyte Quality
NCT ID: NCT06235294
Last Updated: 2024-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
88 participants
INTERVENTIONAL
2024-09-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will take a daily capsule of resveratrol or placebo during the 3 months preceding their IVF treatment. They will then follow the same treatment protocol as non-participant patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants who meet the inclusion and exclusion criteria will be randomly assigned to one of the following groups:
1. Resveratrol (study group) or
2. Placebo (control group).
Supplementation
Women in the study group will take a daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene). Women from control group will take a daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), a vitamin widely prescribed to women who intend to achieve pregnancy for prevention of neural tube defects). Participants will be instructed to take the capsules by morning, every day during the 3 months preceding their IVF treatment. Oral intake of resveratrol/placebo will be discontinued after oocyte retrieval due to the potential adverse effects of resveratrol on endometrial decidualization. Package of resveratrol and placebo will be identical. Compliance of the participant to the intervention will be measured using capsule count. Participants will be asked to keep their usual lifestyle including nutrition and physical activity level.
Ovarian stimulation
GnRH antagonist protocol will be used in all the patients. On day 2 or 3 of the menstrual cycle, daily subcutaneous (SC) injections of rFSH are given up to the day of human chorionic gonadotropin (hCG) administration, when at least three leading follicles reached a mean diameter of 17 mm. Doses of rFSH range from 150 to 300 IU/day depending on the women's age, body mass index (BMI), AFC and AMH. Administration of a daily dose of 0.25 mg of gonadotropin releasing hormone antagonist (GnRHa) (Cetrotide ®, Merck, Netherlands; or Orgalutran ®, Organon, Netherlands) is initiated when the larger follicle reaches a mean diameter of 14 mm. Transvaginal oocyte retrieval is scheduled to 36 hours after choriogonadotropin alfa (α-hCG) administration. Luteal phase support with progesterone is initiated on the day of the oocyte retrieval with 200 mg of micronized intravaginal progesterone every 8 hours (Progeffik ®, EFIKK, France).
In vitro fertilization and embryo transfer
According to the couples's indication, IVF or ICSI is performed. Fertilization is assessed after 18 hours, and oocyte maturational stage is assessed and registered. Embryo cleavage is assessed every 24 hours. Embryo transfer is performed 5 days after oocyte retrieval under ultrasound guidance. All remaining good quality embryos will be vitrified and transferred in subsequent menstrual cycles. If fresh transfer is canceled for clinical reasons, frozen embryo transfer will also be scheduled. Before frozen embryo transfer, patients will start exogenous hormone therapy for endometrial preparation. This therapy is initiated on day 1 of menstrual cycle and consists of 150 mcg of estradiol transdermal patches (Dermestril®, BGP, Lisboa, Portugal) replaced every 3 days. On day 12-14, a pelvic ultrasound is performed to assess endometrial development. If the endometrial thickness is \> 7 mm, 400 mg vaginal micronized progesterone (Cyclogest®, Gedeon Richter, Budapest, Hungria) twice daily was added to the treatment scheme. Fourteen days after oocyte retrieval a quantitative serum value of β-hCG is obtained and a transvaginal ultrasound is scheduled one week later in case of a positive result (biochemical pregnancy). Clinical pregnancy is established by the ultrasonography visualization of a gestational sac. Ongoing pregnancy was defined by a viable intrauterine pregnancy of at least 12 weeks duration confirmed on an ultrasound scan. The outcomes of fresh and vitrified-warmed embryo transfer will be analyzed. Live birth was defined as the delivery of one or more live babies. Miscarriage was defined by a spontaneous pregnancy termination before the gestational age of 12 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resveratrol
Daily capsule of 200 mg Polygonum cuspidatum yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene)
Resveratrol
Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
Placebo
Daily capsule of 400 mcg folic acid.
Folic acid
Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resveratrol
Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
Folic acid
Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ovarian stimulation with GnRH-antagonist protocol
* Age 35-40 years old
Exclusion Criteria
* Low ovarian reserve (AMH \< 1.1. ng/mL)
* Poor response to ovarian stimulation (\< 3 oocytes)
* Polycystic ovarian syndrome (Rotterdam criteria)
* Ovarian endometriosis (endometrioma \> 30 mm)
* Uterine anomalies (congenital or acquired)
* Diabetes Mellitus
* Concurrent use of any vitamin (except folic acid)
35 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unidade Local de Saúde de Coimbra, EPE
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA-01-23
Identifier Type: -
Identifier Source: org_study_id